Viridian Therapeutics (VRDN) to Announce Quarterly Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($1.0229) per share and revenue of $0.0310 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.87) EPS. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $19.51 on Wednesday. The company has a 50-day simple moving average of $17.85 and a two-hundred day simple moving average of $22.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. Viridian Therapeutics has a one year low of $13.18 and a one year high of $34.29. The company has a market capitalization of $2.01 billion, a PE ratio of -5.88 and a beta of 0.90.

Wall Street Analyst Weigh In

VRDN has been the subject of a number of research analyst reports. Wells Fargo & Company upgraded Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Wedbush boosted their price target on Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada increased their price objective on Viridian Therapeutics from $34.00 to $35.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Viridian Therapeutics in a research note on Monday, June 29th. Finally, Truist Financial lifted their target price on Viridian Therapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.79.

Insider Activity

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the purchase, the director owned 5,090,928 shares in the company, valued at approximately $86,545,776. This represents a 30.05% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds have recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in Viridian Therapeutics in the 3rd quarter valued at about $52,000. US Bancorp DE grew its holdings in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares in the last quarter. Sei Investments Co. acquired a new stake in Viridian Therapeutics during the 2nd quarter worth approximately $147,000. Persistent Asset Partners Ltd purchased a new position in Viridian Therapeutics in the 4th quarter valued at approximately $176,000. Finally, Creative Planning purchased a new position in Viridian Therapeutics in the second quarter worth approximately $179,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.